LIPITOR Drug Patent Profile

When do Lipitor patents expire, and when can generic versions of Lipitor launch?

Lipitor is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lipitor

A generic version of LIPITOR was approved as atorvastatin calcium by APOTEX INC on May 29^th, 2012.

Summary for LIPITOR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	229
Patent Applications:	6,077
Drug Prices:	Drug price information for LIPITOR
Drug Sales Revenues:	Drug sales revenues for LIPITOR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LIPITOR
What excipients (inactive ingredients) are in LIPITOR?	LIPITOR excipients list
DailyMed Link:	LIPITOR at DailyMed

See drug prices for LIPITOR

See drug sales revenues for LIPITOR

Recent Clinical Trials for LIPITOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Beijing Tsinghua Chang Gung Hospital	PHASE4
NYU Langone Health	Phase 4
Gannex Pharma Co., Ltd.	Phase 1

See all LIPITOR clinical trials

Pharmacology for LIPITOR

Drug Class	HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors

US Patents and Regulatory Information for LIPITOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-001	Dec 17, 1996	AB	RX	Yes	No
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-004	Apr 7, 2000	AB	RX	Yes	Yes
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-002	Dec 17, 1996	AB	RX	Yes	No
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-003	Dec 17, 1996	AB	RX	Yes	No

Expired US Patents for LIPITOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-002	Dec 17, 1996	5,385,929
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-002	Dec 17, 1996	RE40667*PED
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-003	Dec 17, 1996	5,385,929
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-001	Dec 17, 1996	5,385,929
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-003	Dec 17, 1996	RE40667*PED
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-004	Apr 7, 2000	5,969,166

International Patents for LIPITOR

See the table below for patents covering LIPITOR around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	680963
Canada	1268768	INHIBITEURS DE LA SYNTHESE DU CHOLESTEROL DE TYPE TRANS-6-[2-(2 OU 4-CARBOXAMIDO(SUBSTITUE)PYRROL-1- YL)ALKYL]-4-HYDROXYPYRAN-2-ONE (TRANS-6-[2-(3- OR 4-CARBOXAMIDO-SUBSTITUTED PYRROL- 1-YL)ALKYL]-4-HYDROXYPYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS)
Poland	324496
Spain	2168318
China	1190955
New Zealand	234576	(R-(R * ,R * ))-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1- METHYLETHYL)-3-PHENYL-4-((PHENYLAMINO)-CARBONYL)-1H-PYRROLE-1-HEPTANOIC ACID AND SALTS THEREOF, AND PHARMACEUTICAL COMPOSITIONS

Supplementary Protection Certificates for LIPITOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0247633	9790036	Sweden		PRODUCT NAME: ATORVASTIN OCH FARMACEUTISKT GODTAGBARA SALTER DäRAV; NAT. REGISTRATION NO/DATE: 13415 19970417; FIRST REG.: GB PL00018/0240 19961107
1003503	C01003503/01	Switzerland		PRODUCT NAME: AMLODIPIN + ATORVASTATIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57633 05.07.2006
0247633	62/1997	Austria		PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
1003503	05C0048	France		PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
0247633	C970034	Netherlands		PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0247633	97C0118	France		PRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107

LIPITOR Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Lipitor (atorvastatin) is a statin medication used to lower cholesterol and prevent cardiovascular disease. Its market performance is characterized by an initial period of significant growth driven by patent exclusivity, followed by a sharp decline in revenue post-patent expiration and the introduction of generics.

What is Lipitor's Primary Mechanism of Action and Therapeutic Use?

Lipitor is a synthetic lipid-lowering agent that inhibits HMG-CoA reductase, an enzyme crucial for cholesterol synthesis in the liver. By blocking this enzyme, atorvastatin reduces the production of cholesterol, thereby lowering levels of low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol. It also has a modest effect on increasing high-density lipoprotein (HDL) cholesterol, or "good" cholesterol, and reducing triglycerides.

The primary therapeutic indication for Lipitor is the treatment of hypercholesterolemia, a condition characterized by elevated cholesterol levels in the blood. It is prescribed to reduce the risk of myocardial infarction (heart attack), stroke, and the need for revascularization procedures in patients with or at high risk of coronary heart disease (CHD). This broad applicability to a significant patient population has been a key driver of its market success.

How Has Lipitor's Patent Status Impacted its Market Trajectory?

Lipitor's market trajectory is inextricably linked to its patent life. Originally developed by Parke-Davis (later Pfizer) and launched in 1997, the drug benefited from a period of market exclusivity granted by its patent.

• Patent Exclusivity Period (1997-2011): During this phase, Lipitor was the sole branded atorvastatin product available. This exclusivity allowed Pfizer to command premium pricing and capture a dominant market share. Sales grew exponentially, making Lipitor one of the best-selling drugs in history.
• Patent Expiration (November 30, 2011): The expiration of key patents for Lipitor in the United States and other major markets opened the door for generic manufacturers. This event marked the beginning of a precipitous decline in branded Lipitor sales.
• Generic Competition: Following patent expiration, numerous generic versions of atorvastatin entered the market. These generics are bioequivalent to Lipitor but are sold at significantly lower prices, directly eroding the market share and revenue of the branded drug.

The transition from patent exclusivity to generic competition is a predictable pattern in the pharmaceutical industry. For Lipitor, this transition was particularly pronounced due to its massive sales volume and the subsequent aggressive pricing strategies of generic competitors.

What Were Lipitor's Peak Sales and Revenue Performance?

Lipitor achieved record-breaking sales during its patent-protected period, reaching its zenith in the mid-to-late 2000s.

• Peak Annual Sales: Lipitor's annual sales peaked in 2007, reaching approximately $12.7 billion USD [1, 2]. This figure represents the highest point of revenue generated by a single pharmaceutical product in history at that time.
• Cumulative Sales: Over its lifespan as a branded product, Lipitor generated hundreds of billions of dollars in revenue. By the time of its patent expiration in late 2011, cumulative sales were estimated to be in excess of $140 billion USD [2].

Pfizer strategically managed the growth of Lipitor through various marketing efforts, expanding indications, and aggressive clinical trial publication, all contributing to its sustained dominance.

How Did Generic Entry Affect Lipitor's Market Share and Revenue Post-2011?

The entry of generic atorvastatin products following Lipitor's patent expiration in late 2011 had a profound and immediate impact on its market share and revenue.

• Revenue Decline: Within the first year of generic competition, branded Lipitor's revenue experienced a drastic reduction. Pfizer reported that Lipitor sales declined by approximately 50% in the first quarter of 2012 compared to the same period in 2011 [3]. This trend continued, with annual revenues dropping to figures in the hundreds of millions of dollars.
• Market Share Erosion: Generic atorvastatin quickly captured the majority of the statin market. The lower cost of generics made them the preferred choice for many payers, pharmacies, and patients. The market share of branded Lipitor became negligible as healthcare systems transitioned to generic prescribing.
• Pricing Impact: The price differential between branded Lipitor and generic atorvastatin was substantial. Generic atorvastatin is typically sold at 80-90% less than the branded product's peak price, reflecting the competitive nature of the generic pharmaceutical market [4].

This rapid market shift is a classic example of the "patent cliff" phenomenon, where a pharmaceutical company experiences a significant loss of revenue and market share upon the expiration of a blockbuster drug's patent.

What is the Current Market Status of Lipitor and Generic Atorvastatin?

Currently, Lipitor exists primarily as a generic medication. The branded product still exists, but its market presence is minimal compared to the widespread use of generic atorvastatin.

• Generic Dominance: Generic atorvastatin is a widely prescribed medication, available from numerous manufacturers. It remains a first-line therapy for hypercholesterolemia and cardiovascular risk reduction due to its efficacy, safety profile, and cost-effectiveness.
• Market Volume: The total market volume for atorvastatin (including both branded and generic) remains substantial, reflecting the high prevalence of cardiovascular disease and the established therapeutic role of statins. However, the revenue generated is now distributed among multiple generic manufacturers.
• Branded Lipitor's Role: Pfizer continues to market branded Lipitor, but its sales are a fraction of its former glory, primarily serving a niche market or patients with specific preferences. Its market share is now insignificant in the context of the overall atorvastatin market.
• Pricing: The price of generic atorvastatin is highly competitive, with ongoing pressure from payers and pharmacy benefit managers (PBMs) to ensure affordability. Prices for a 30-day supply can range from a few dollars to under $20, depending on insurance coverage and pharmacy.

The long-term market status of atorvastatin is that of a mature, off-patent drug that continues to play a vital role in public health, with the vast majority of its prescription volume being filled by generic versions.

What Are the Key Financial Implications for Pfizer and Competitors?

The financial implications of Lipitor's lifecycle are significant for both Pfizer and its competitors.

• Pfizer's Experience:
  • Massive Revenue Generation: Prior to patent expiration, Lipitor was a primary revenue driver for Pfizer, contributing billions of dollars annually to its top line and fueling significant profits.
  • Patent Cliff Impact: The loss of Lipitor exclusivity necessitated a strategic shift for Pfizer. The company faced a substantial revenue gap, prompting efforts in portfolio diversification, mergers and acquisitions (M&A), and the development of new blockbuster drugs. This period was often referred to as Pfizer's "patent cliff" challenge.
  • Investment in R&D: The profits generated by Lipitor helped fund Pfizer's extensive research and development efforts, supporting the discovery and development of subsequent pipeline drugs.
• Generic Manufacturers' Opportunity:
  • Market Entry and Growth: Lipitor's patent expiration presented a significant market opportunity for generic pharmaceutical companies. Manufacturers with the ability to produce high-quality, cost-effective atorvastatin quickly gained market share.
  • Increased Competition: The influx of generic competitors intensified price competition, leading to lower margins for individual manufacturers but a substantial increase in the overall volume of affordable atorvastatin available to patients.
  • Established Market: Entering the atorvastatin market provided generic companies with a stable revenue stream from a well-established and widely prescribed medication.

The Lipitor story serves as a textbook case study in pharmaceutical market dynamics, illustrating the enormous financial rewards of patent exclusivity and the dramatic market disruption that follows patent expiration.

What Regulatory Factors Influenced Lipitor's Market Performance?

Several regulatory factors have consistently influenced Lipitor's market performance throughout its lifecycle.

• FDA Approval: The initial U.S. Food and Drug Administration (FDA) approval in August 1997 for the treatment of hypercholesterolemia was the cornerstone of its market entry. Subsequent approvals for expanded indications, such as reducing the risk of cardiovascular events, broadened its patient base and market potential.
• Patent Protection and Extension: The duration and strength of Lipitor's patents, granted by the United States Patent and Trademark Office (USPTO) and equivalent bodies internationally, were critical. Legal challenges and patent extensions could delay generic entry, as seen in various instances where litigation extended the branded drug's exclusivity period.
• Generic Drug Approval Process: The FDA's abbreviated new drug application (ANDA) process allows generic manufacturers to demonstrate bioequivalence to the reference listed drug (Lipitor in this case) without requiring extensive new clinical trials. This streamlined process facilitates rapid market entry for generics once patents expire.
• Pricing and Reimbursement Policies: While not directly dictating drug prices, government and private payer reimbursement policies significantly influence market access and physician prescribing habits. The cost-effectiveness of atorvastatin, particularly in comparison to branded Lipitor, became a major factor in formulary placement and prescription volume, especially after patent expiration.
• Marketing and Promotion Regulations: Regulatory bodies like the FDA govern how pharmaceutical companies, including Pfizer and generic manufacturers, can market and promote their products. These regulations impact advertising claims, direct-to-consumer advertising, and physician detailing, all of which played a role in shaping market perception and demand for Lipitor and its generic alternatives.

What are the Future Market Prospects for Atorvastatin?

The future market prospects for atorvastatin are stable, characterized by continued high prescription volumes driven by its established efficacy and the ongoing prevalence of cardiovascular disease, with generic versions dominating.

• Sustained Demand: Atorvastatin is expected to remain a cornerstone therapy for dyslipidemia and cardiovascular risk reduction. Global guidelines for managing cardiovascular disease continue to recommend statins as first-line treatment.
• Generic Market Maturity: The atorvastatin market is highly mature and competitive. Further significant growth in overall market value is unlikely, as the market is characterized by price-sensitive generic competition.
• Biosimilar Competition (Not Applicable): Atorvastatin is a small molecule drug, not a biologic. Therefore, biosimilar competition, which applies to biologic drugs, is not a factor.
• Competition from Newer Therapies: While atorvastatin will remain dominant, emerging novel lipid-lowering therapies, such as PCSK9 inhibitors and bempedoic acid, are gaining traction for specific patient populations or those who are statin-intolerant or have residual cardiovascular risk despite statin therapy. These newer drugs represent a potential, albeit niche, challenge to atorvastatin's absolute dominance in certain segments.
• Focus on Patient Adherence: Future market efforts will likely focus on improving patient adherence to statin therapy, ensuring optimal cardiovascular outcomes. This may involve combination therapies or patient education initiatives.

The market for atorvastatin will continue to be characterized by high volume and low prices, a direct consequence of its successful patent expiration and the subsequent genericization.

Key Takeaways

Lipitor's market journey exemplifies the pharmaceutical lifecycle from blockbuster success to generic commodity. Its trajectory demonstrates the profound impact of patent exclusivity, the economic disruption of patent expiration, and the enduring importance of cost-effective therapies in managing widespread chronic diseases. The drug’s transition from a multi-billion dollar branded product to a widely accessible generic underscores the dynamic interplay between innovation, intellectual property, and public health economics.

Frequently Asked Questions

How much did Lipitor cost at its peak?

At its peak, a month's supply of branded Lipitor could cost upwards of $200-$300 USD without insurance, depending on the dosage and pharmacy [5].

What are the main side effects of atorvastatin?

Common side effects of atorvastatin include muscle pain, joint pain, diarrhea, nausea, and headache. More serious but rare side effects can include severe muscle damage (rhabdomyolysis) and liver problems [6].

Are there any branded atorvastatin products still available?

Yes, Pfizer continues to market branded Lipitor, but its market share is minimal, and it is significantly more expensive than generic atorvastatin.

What is the global market size for atorvastatin generics?

The global market for atorvastatin generics is substantial, with annual sales in the billions of dollars, though specific figures fluctuate based on pricing and market dynamics. However, its revenue is distributed among numerous manufacturers.

Can a patient switch from branded Lipitor to a generic atorvastatin without consulting a doctor?

Patients are generally advised to consult their physician or pharmacist when switching medications, even between a branded drug and its generic equivalent, to ensure continued efficacy and management of their condition.

DrugChatter Q&A for LIPITOR

How often do you experience lipitor cravings?
What are the potential interactions with lipitor and turmeric?
Can lipitor and multivitamins be taken safely at the same time?
Is lipitor s role in cholesterol reduction matched by red wine?
How long was lipitor taken for?